LOGIN  |  REGISTER
Assertio

List of Big Pharma Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 857.20
12.93 1.53
3.01M
899.32M
US$ 770.900B
US$ 154.99
-1.16 -0.74
7.72M
2.41B
US$ 373.530B
US$ 196.25
17.05 9.51
7.20M
1.77B
US$ 347.360B
US$ 82.20
4.33 5.56
8.66M
3.37B
US$ 277.010B
US$ 74.80
1.22 1.66
5.73M
3.10B
US$ 231.880B
US$ 40.86
-0.20 -0.49
171,214
5.52B
US$ 225.550B
US$ 106.61
1.18 1.12
1.18M
2.00B
US$ 213.220B
US$ 83.29
0.28 0.34
22.81M
2.53B
US$ 210.720B
US$ 292.80
1.64 0.56
1.89M
537.53M
US$ 157.390B
US$ 25.56
0.03 0.12
35.45M
5.67B
US$ 144.930B
US$ 53.95
-0.55 -1.01
2.05M
2.51B
US$ 135.410B
US$ 105.25
1.17 1.12
8.25M
1.25B
US$ 131.560B
US$ 462.11
3.11 0.68
1.31M
257.53M
US$ 119.010B
US$ 54.43
0.53 0.98
10.39M
2.03B
US$ 110.490B
US$ 36.61
0.44 1.22
4.31M
2.04B
US$ 74.680B
US$ 680.00
6.40 0.95
584,052
108.07M
US$ 73.490B
US$ 13.90
0.36 2.66
1.68M
3.17B
US$ 44.060B
US$ 639.00
-0.41 -0.06
197,560
59.80M
US$ 38.210B
US$ 250.00
-6.45 -2.52
883,001
128.98M
US$ 32.240B
US$ 122.75
2.92 2.44
603,829
239.74M
US$ 29.430B
US$ 5.71
0.06 1.06
226,886
3.93B
US$ 22.440B
US$ 136.57
-0.76 -0.55
1.24M
145.72M
US$ 19.900B
US$ 16.57
0.32 1.97
16.94M
1.13B
US$ 18.720B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 9.69
-0.08 -0.82
3,438
1.79B
US$ 17.350B
US$ 372.83
2.25 0.61
397,928
44.64M
US$ 16.640B
US$ 32.85
0.49 1.51
3.94M
444.30M
US$ 14.600B
US$ 81.36
2.05 2.58
2.50M
178.90M
US$ 14.560B
US$ 21.77
0.47 2.21
1.82M
635.24M
US$ 13.830B
US$ 35.75
2.76 8.37
17.97M
384.82M
US$ 13.760B
US$ 71.27
0.85 1.21
1.40M
192.65M
US$ 13.730B
US$ 10.86
0.06 0.56
7.51M
1.19B
US$ 12.920B
US$ 64.86
0.01 0.02
996,550
190.58M
US$ 12.360B
US$ 113.97
-1.05 -0.91
934,659
101.25M
US$ 11.540B
US$ 63.48
0.00 0.00
0
181.51M
US$ 11.520B
US$ 65.29
-0.65 -0.99
1.44M
158.89M
US$ 10.370B
US$ 105.35
-2.60 -2.41
1.15M
95.52M
US$ 10.060B

Latest Big Pharma Stock News


U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV Prevention Choice  FDA to Review Applications Under Priority Review, with a PDUFA Date of June 19, 2025  Gilead Also Recently Submitted Applications for Lenacapavir for PrEP to the European Medicines Agency That Will Be Reviewed Under Accelerated Assessment Review Timeline  FOSTER CITY, Calif. / Feb 18, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that... Read more


Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and N...

Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen’s rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront,... Read more


Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System

    MINNEAPOLIS, Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, supporting the development and manufacture of immune cell- and stem cell-based therapies. The TcBuster System has been widely used by researchers to introduce large cargo genetic modifications in a range... Read more


    Merck: WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications

      WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union RAHWAY, N.J. / Feb 18, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, as monotherapy for: The treatment of adult patients with von Hippel-Lindau... Read more


      Alvotech and Teva Pharmaceutical Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

      REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech’s... Read more


      Regeneron Pharmaceuticals: Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

      If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placebo BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesi... Read more


      PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY

      Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W, and Y) Broad serogroup coverage in one vaccine reduces injections to help improve vaccination rates and help protect more US adolescents and young adults PHILADELPHIA / Feb 17, 2025 / Business Wire / GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for... Read more


      Bristol-Myers Squibb: New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

      No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, clinical response was maintained in nearly half of patients for Psoriasis Area and Severity Index (PASI) 90 in the POETYK PSO long-term extension trial PRINCETON, N.J. / Feb 16, 2025 / Business Wire / Bristol Myers Squibb (NYSE:BMY) today announced new five-year results from... Read more


      IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc...

      IMFINZI reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone WILMINGTON, Del. / Feb 14, 2025 / Business Wire / Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free survival (EFS) and overall survival (OS) versus neoadjuvant... Read more


      Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

      Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing Reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28) Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion Submitted three investigational mRNA products for regulatory... Read more


      Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer

      TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation status TALZENNA + XTANDI improved median OS by almost 9 months in unselected patients (Cohort 1) and by 14 months in patients selected for HRR mutations (Cohort 2) versus standard of care XTANDI NEW... Read more


      Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

      PRINCETON, N.J. / Feb 13, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival (RFS). The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab. “We are... Read more


      Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

      Achieved Fourth Quarter and Full Year 2024 Global Net Product Revenues of $451 Million and $1,646 Million, Respectively, Representing 30% and 33% Growth Compared to Same Periods in 2023  Supplemental NDA for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Accepted by FDA, with March 23, 2025 PDUFA Date  Reiterates Product Sales and Profitability Guidance and Provides Additional 2025 Financial Guidance  Company to Host and Webcast R&D... Read more


      Johnson & Johnson: New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody...

      Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by >75%, including autoantibodies, potentially without affecting other immune functions SPRING HOUSE, Pa., Feb. 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the publication of data detailing the differentiated molecular properties of nipocalimab, an investigational neonatal Fc receptor (FcRn)... Read more


      U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

      Approval is based on positive data from the Phase 3 ECHELON-3 trial, which demonstrated ADCETRIS regimen reduced the risk of death by 37%, a statistically significant, clinically meaningful improvement in overall survival (OS), compared to lenalidomide and rituximab plus placebo ECHELON-3 is the first Phase 3 trial to demonstrate OS advantage over lenalidomide and rituximab plus placebo for patients with at least 2 prior lines of therapy with R/R diffuse large B-cell... Read more


      FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

      Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the currently available oral solution New tablet formulation may provide greater freedom and independence for people with SMA thanks to simplified dose administration SOUTH SAN FRANCISCO, Calif. / Feb 12, 2025 / Business Wire / Genentech, a member of the Roche... Read more


      AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

      Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immu... Read more


      Royalty Pharma Announces R&D Funding Collaboration With Biogen

      NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). “We are excited to collaborate with Biogen on litifilimab,”... Read more


      Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results

      Product Sales Excluding Veklury Increased 8% Year-Over-Year to $26.8 billion for Full Year 2024 Biktarvy Sales Increased 13% Year-Over-Year to $13.4 billion for Full Year 2024 Oncology Sales Increased 12% Year-Over-Year to $3.3 billion for Full Year 2024 FOSTER CITY, Calif. / Feb 11, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024. “Gilead delivered another exceptionally... Read more


      Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

      Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway Abelacimab is currently in Phase 3 development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation Acquisition adds a late-stage asset and is aligned with Novartis strategic focus, strength and expertise in the cardiovascular therapeutic ar... Read more


      Health Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with...

      Approval is based on the Phase 3 KEYNOTE-671 Trial KIRKLAND, QC, Feb. 11, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment,... Read more


      Regeneron Pharmaceuticals: Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

      Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma... Read more


      Royalty Pharma Reports Q4 and Full Year 2024 Results

      Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024 Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in Q4 2024 and $2,769 million for FY 2024 Full year 2025 guidance: Portfolio Receipts expected to be $2,900 to $3,050 million excluding future transactions NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for... Read more


      Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

      Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of la/mUC At nearly 30 months of follow-up in the Phase 3 EV-302 trial, the combination doubled median overall survival and progression-free survival compared to chemotherapy, with no new safety signals identified NEW YORK & TOKYO / Feb 10, 2025 / Business Wire / Pfizer... Read more


      Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

      Full year product revenue of $11.02 billion, a 12% increase compared to full year 2023  Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion  ALYFTREK™ approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX™ approved in the U.S. for moderate-to-severe acute pain  Diverse late-stage clinical pipeline accelerates with four programs in pivotal development  Stuart Arbuckle, Chief Operating Officer, announces... Read more


      Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

      Total revenues of $1.2 billion (+16% Y/Y) in the fourth quarter 2024 and $4.2 billion (+15% Y/Y) for the full year 2024 Jakafi® (ruxolitinib) net revenues of $773 million (+11% Y/Y) in the fourth quarter 2024 and $2.8 billion (+8% Y/Y) for the full year 2024; Jakafi net revenues guidance range of $2,925 - $2,975 million for the full year 2025 Opzelura® (ruxolitinib) cream net revenues of $162 million (+48% Y/Y) in the fourth quarter 2024 and $508 million (+50% Y/Y)... Read more


      Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

      Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate With these data, Breyanzi demonstrates efficacy and manageable safety in a fifth cancer type, the most of any CD19-directed CAR T cell therapy PRINCETON, N.J. / Feb 10, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi® (lisocabtagene maraleucel) in adult patients with relapsed or refractory... Read more


      Regeneron Pharmaceuticals: Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic...

      At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%, 58%, 40% and 24% achieved last assigned dosing intervals of ≥3, ≥4, ≥5 and 6 months, respectively At three years, the vast majority of patients who switched to EYLEA HD from a fixed 2-month dosing regimen with EYLEA® (aflibercept) Injection 2 mg maintained visual and... Read more


      AbbVie: U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options

      EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies Antimicrobial resistance (AMR) could lead to over 39 million deaths worldwide by 2050, and new treatments... Read more


      Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years

      More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one year sustained it at two years Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis INDIANAPOLIS, Feb. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced... Read more


      New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis

      Nearly half of patients on Gazyva plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, compared to standard treatment alone Analysis showed consistent CRR benefit across patient subgroups highlighting potential to treat a broad patient population with high unmet need Gazyva is the only anti-CD20 monoclonal antibody in a phase III study to demonstrate CRR benefit, which is associated with... Read more


      Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

      INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United States Phase 3 Programs for Osavampator in Major... Read more


      Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

      Performance Reflects Progress Toward Delivering Sustained, Top-Tier Growth Fourth Quarter Revenues were $12.3 Billion, Increasing 8% (+9% Adjusting for Foreign Exchange); GAAP Earnings Per Share (EPS) was $0.04 and Non-GAAP EPS was $1.67 Growth Portfolio Revenues were $6.4 Billion, Increasing 21% (+23% Adjusting for Foreign Exchange) Full-Year Revenues were $48.3 Billion, Increasing 7% (+9% Adjusting for Foreign Exchange); GAAP Loss Per Share was $(4.41) and Non-GAAP... Read more


      Eli Lilly reports full Q4 2024 financial results and provides 2025 guidance

      Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline progress included the approval of Zepbound in the U.S. for moderate-to-severe obstructive sleep apnea in adults with obesity and the approval of Omvoh in the U.S. for moderately to severely active Crohn's disease. Notable recent events include the pending acquisition of Scorpion Therapeutics, Inc's... Read more


      AstraZeneca’s Full Year and Q4 2024 results

      Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively CAMBRIDGE, England / Feb 06, 2025 / Business Wire / AstraZeneca: Revenue and EPS summary     FY 2024 % Change     Q4 2024 % Change     $m Actual CERi     $m Actual CER - Product Sales   50,938 16 19     13,362 18... Read more


      Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large...

      Expansion of the waveLINE clinical development program demonstrates company’s progress in advancing research in hematologic malignancies RAHWAY, N.J. / Feb 06, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin and prednisone (R-CHP) compared to... Read more


      FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

      Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved BRIDGEWATER, N.J., Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application... Read more


      Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

      Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion. Operating profit was positively impacted by gross-to-net sales adjustments in the US and negatively impacted by impairment losses. Sales in North America Operations increased by 30% in Danish kroner (30% at CER). Sales in International Operations increased by 17% in Danish kroner (19% at CER). Sales within Diabetes and Obesity care increased by 26% in Danish... Read more


      Bio-Techne Releases Second Quarter Fiscal 2025 Results

      MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2024. Second Quarter FY2025 Highlights Second quarter organic revenue increased by 9% (9% reported) to $297.0 million. GAAP earnings per share (EPS) was $0.22 versus $0.17 one year ago. Delivered adjusted EPS of $0.42 compared to $0.40 one year ago. Improving biopharma end-market conditions combined with continued... Read more


      Amgen Reports Fourth Quarter And Full Year 2024 Financial Results

      THOUSAND OAKS, Calif., Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023. "Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four therapeutic areas," said Robert A. Bradway, chairman and... Read more


      Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results

      Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 9% Fourth-Quarter GAAP EPS Was $1.48; Non-GAAP EPS Was $1.72; GAAP and Non-GAAP EPS Include a Charge of $0.23 per Share Related to Certain Business Development Transactions Full-Year Worldwide Sales Were $64.2 Billion, an Increase of 7% From Full Year 2023; Excluding the Impact of Foreign Exchange, Growth Was 10% KEYTRUDA... Read more


      Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance

      Full-Year 2024 Revenues of $63.6 Billion, Reflecting 7% Year-over-Year Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 12% Operationally Full-Year 2024 Reported(2) Diluted EPS of $1.41 and Adjusted(3) Diluted EPS of $3.11 Fourth-Quarter 2024 Revenues of $17.8 Billion, Reflecting 21% Year-over-Year Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 11% Operationally Fourth-Quarter... Read more


      Regeneron Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion

      Fourth quarter 2024 revenues increased 10% to $3.79 billion versus fourth quarter 2023 Full year 2024 revenues increased 8% to $14.20 billion versus 2023; excluding RonapreveTM(a)(b), revenues increased 10% Fourth quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 15% to $3.70 billion versus fourth quarter 2023; full year 2024 Dupixent global net sales increased 22% to $14.15 billion versus 2023 Fourth quarter 2024 U.S. net... Read more


      FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

      Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo in addition to wet, or neovascular age-related macular degeneration (AMD) SOUTH SAN FRANCISCO, Calif. / Feb 04, 2025 / Business Wire / Genentech, a member of the Roche Group... Read more


      United Therapeutics Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

      Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression Top line data expected in the first half of 2026 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 04, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced full enrollment of the TETON 1 study evaluating the use of Tyvaso® (treprostinil) inhalation solution... Read more


      Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

      MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President... Read more


      United Therapeutics Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial

      First-ever human clinical trial of a xeno-organ intended to allow for potential registration through the submission of a Biologics License Application to the U.S. FDA First xenotransplant is expected to occur around mid-year 2025 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 03, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has cleared... Read more


      Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial

      BRAFTOVI in combination with cetuximab and mFOLFOX6 showed statistically significant and clinically meaningful improvement in progression-free survival and overall survival in patients with metastatic colorectal cancer with a BRAF V600E mutation BRAFTOVI combination regimen received accelerated approval for treatment-naïve patients in December 2024 Results to be shared with the U.S. FDA to support potential conversion to full approval NEW YORK / Feb 03, 2025 / Business... Read more


      BioNTech Completes Acquisition of Biotheus

      Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers With the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodies Biotheus will become a new indirect Chinese subsidiary of BioNTech, adding a local research and development hub... Read more


      Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults

      RAHWAY, N.J. / Jan 31, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. The... Read more